App-Quantinova.ai

Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC).

Scott J. Parker - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use.

Celestia S. Higano - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC).

Lauren Christine Harshman - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Real-world experience of therapeutic sequencing and time to first anticancer intervention (ACI) following sipuleucel-T (sip-T): Initial data from the PROCEED registry.

A. Oliver Sartor - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Docetaxel

Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.

Guru Sonpavde - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

The prevalence of objectively measurable disease in phase III trials of metastatic castration-resistant prostate cancer (mCRPC).

Ankit Madan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.

Karim Fizazi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Randomized phase II trial of docetaxel plus prednisolone with or without androgen deprivation treatment in castration-resistant prostate cancer.

Jae Ho Jeong - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.

Francesca Maines - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

ProCAID: A phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone (DP) chemotherapy for metastatic castration resistant prostate cancer (mCRPC).

Simon J. Crabb - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer.

Vincenza Conteduca - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

Karen A. Autio - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Novel agents’ sequencing following first-line docetaxel in mCRPC patients: CAPRO study.

Javier Puente - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Pharmacokinetic food-effect study of abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC): The ABIFOOD trial (EudraCt number: 2012-003226-25).

M. Espinosa - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Analysis of the temporal relationship between patient-reported outcomes (PROs) and overall survival (OS) and radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).

Shana Traina - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Evaluating abiraterone responses in African Americans with metastatic CRPC.

Michael D. Stolten - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Patient stem cell (SC)-derived prostate cancer (PC) organoids (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential.

Anna C. Ferrari - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Chemotherapy in metastatic hormone-naïve prostate cancer: Pooled analysis of randomized clinical trials.

Paolo Fabbri - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Docetaxel chemotherapy in metastatic castration-resistant prostate cancer (mCRPC): Cost of care for Medicare and commercially insured men.

Andrew J. Armstrong - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).

Daniel J. George - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Filters

2459 Abstracts